tiprankstipranks
Trending News
More News >
Tenax Therapeutics (TENX)
NASDAQ:TENX
US Market

Tenax Therapeutics (TENX) AI Stock Analysis

Compare
573 Followers

Top Page

TE

Tenax Therapeutics

(NASDAQ:TENX)

Rating:36Underperform
Price Target:
Tenax Therapeutics' overall score reflects substantial financial challenges due to an absence of revenue and consistent losses, heavily reliant on equity financing. Technical indicators suggest neutral momentum, but poor financial performance and valuation overshadow any potential stability.
Positive Factors
Clinical Trials
Management expressed high conviction in the likelihood of success for oral levosimendan’s Phase 3 trial.
Patient Adherence
Extraordinary patient adherence in the ongoing Ph3 LEVEL trial with over 95% of randomized patients remaining on therapy.
Regulatory Engagement
Proactive and positive engagement with the FDA and intellectual property protection through 2040+.
Negative Factors
Financial Performance
TENX reported 4Q24 total operating expenses of $7.3M, above the estimate of $4.7M, driven by higher R&D spending.
Investment Perception
The investment community underappreciates statements related to patient adherence, with more than 95% of patients remaining on therapy or continuing participation.

Tenax Therapeutics (TENX) vs. SPDR S&P 500 ETF (SPY)

Tenax Therapeutics Business Overview & Revenue Model

Company DescriptionTenax Therapeutics, Inc., a specialty pharmaceutical company, engages in identifying, developing, and commercializing products for cardiovascular and pulmonary diseases in the United States and Canada. It develops TNX-103 and TNX-102 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of pulmonary arterial hypertension. The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014. Tenax Therapeutics, Inc. was founded in 1967 and is headquartered in Morrisville, North Carolina.
How the Company Makes MoneyTenax Therapeutics makes money primarily through the development and commercialization of its pharmaceutical products. The company's revenue model is centered on the successful advancement of its drug candidates through clinical trials, regulatory approvals, and eventual market entry. Revenue streams include potential product sales, licensing agreements, and partnerships with other pharmaceutical companies. Key factors contributing to its earnings include the successful demonstration of clinical efficacy and safety of its drug candidates, strategic alliances with industry partners, and potential collaborations for the distribution and marketing of its products. The company's focus on targeting niche markets with high unmet medical needs may also play a significant role in its revenue generation strategies.

Tenax Therapeutics Financial Statement Overview

Summary
Tenax Therapeutics shows financial instability with zero revenue, negative profitability metrics, and ongoing operational losses. The company's strong equity position and liquidity are primarily due to external financing, which is unsustainable without revenue growth.
Income Statement
5
Very Negative
The company has consistently reported zero revenue over the years, leading to negative gross profit and net income figures. There is no visible revenue growth trajectory, and profitability metrics such as EBIT and EBITDA are negative, indicating significant losses.
Balance Sheet
30
Negative
The company has a strong equity position with zero total debt and a high equity ratio. However, the lack of revenue and consistent net losses are concerning for long-term sustainability. The cash reserves have been bolstered, which improves liquidity but does not offset the operational losses.
Cash Flow
10
Very Negative
Operating and free cash flows are negative, reflecting ongoing cash burn. While financing activities have significantly increased cash reserves, this reliance on external financing is not sustainable without revenue generation. The cash flow situation poses a risk if the company cannot turn operations profitable.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue0.000.000.000.000.000.00
Gross Profit0.000.00-7.57K-113.33K-108.98K-114.75K
EBITDA-13.79M-17.58M-8.23M-10.93M-32.36M-9.74M
Net Income-24.21M-17.60M-7.71M-11.05M-32.47M-9.85M
Balance Sheet
Total Assets112.06M96.69M11.68M3.40M5.99M6.87M
Cash, Cash Equivalents and Short-Term Investments111.45M94.85M9.79M2.12M5.58M6.71M
Total Debt0.000.00500.90K807.89K290.78K305.04K
Total Liabilities2.77M4.69M3.59M1.91M1.75M2.24M
Stockholders Equity109.29M91.99M8.10M1.49M4.24M4.63M
Cash Flow
Free Cash Flow-16.61M-14.81M-5.90M-12.02M-10.86M-9.28M
Operating Cash Flow-16.61M-14.81M-5.90M-12.01M-10.86M-9.27M
Investing Cash Flow0.000.002.84K-2.32K452.61K20.11K
Financing Cash Flow115.51M99.87M13.57M8.55M10.60M

Tenax Therapeutics Technical Analysis

Technical Analysis Sentiment
Neutral
Last Price5.81
Price Trends
50DMA
5.83
Negative
100DMA
6.01
Negative
200DMA
5.55
Positive
Market Momentum
MACD
-0.02
Positive
RSI
49.28
Neutral
STOCH
24.85
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TENX, the sentiment is Neutral. The current price of 5.81 is below the 20-day moving average (MA) of 5.82, below the 50-day MA of 5.83, and above the 200-day MA of 5.55, indicating a neutral trend. The MACD of -0.02 indicates Positive momentum. The RSI at 49.28 is Neutral, neither overbought nor oversold. The STOCH value of 24.85 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for TENX.

Tenax Therapeutics Risk Analysis

Tenax Therapeutics disclosed 37 risk factors in its most recent earnings report. Tenax Therapeutics reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Tenax Therapeutics Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
51
Neutral
$7.50B0.32-61.87%2.27%17.10%1.59%
51
Neutral
$23.50M-36.31%15.73%51.00%
50
Neutral
$25.16M-66.15%43.03%81.75%
41
Neutral
$35.57M-853.05%34.97%
41
Neutral
$20.78M-161.93%-0.38%
41
Neutral
$26.63M-24.97%38.80%
36
Underperform
$23.81M-39.78%84.17%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
TENX
Tenax Therapeutics
5.81
2.64
83.28%
OVID
Ovid Therapeutics
0.34
-0.40
-54.05%
VYNE
VYNE Therapeutics
1.42
-0.42
-22.83%
PYPD
PolyPid
3.49
-0.51
-12.75%
CGTX
Cognition Therapeutics
0.34
-1.57
-82.20%
GDTC
CytoMed Therapeutics Limited
2.12
0.03
1.44%

Tenax Therapeutics Corporate Events

Executive/Board Changes
Tenax Therapeutics Appoints Interim CFO Thomas McGauley
Neutral
Dec 4, 2024

Tenax Therapeutics, Inc. has appointed Thomas A. McGauley as Interim Chief Financial Officer, effective December 2, 2024. With over 25 years of experience in finance and executive roles, McGauley will lead the company’s financial operations under a consulting agreement with Danforth Advisors. His extensive background includes advisory roles at CBIZ and serving as CFO for various life sciences firms, making him well-suited to guide Tenax’s financial strategy.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Apr 30, 2025